QQ客服 官方微博 反馈留言

	Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
	Jiang, Z.; Li, W.; Hu, X.; Zhang, Q.; Sun, T.; Cui, S.; Wang, S.; Ouyang, Q.; Yin, Y.; Geng, C.
刊名	ANNALS OF ONCOLOGY
	2018
卷号	29
ISSN号	0923-7534
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3535675
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Jiang, Z.,Li, W.,Hu, X.,et al. Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer[J]. ANNALS OF ONCOLOGY,2018,29.
APA	Jiang, Z..,Li, W..,Hu, X..,Zhang, Q..,Sun, T..,...&Wang, X..(2018).Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer.ANNALS OF ONCOLOGY,29.
MLA	Jiang, Z.,et al."Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer".ANNALS OF ONCOLOGY 29(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。